Expression and prognostic significance of Livin in gastric cancer

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2520-2528

  Chung, Cho Yun ^a   Park, Young Lan ^a   Kim, Nuri ^a   Park, Hyung Chul ^a   Park, Hyun Bum ^a   Myung, Dae Seong ^a   Kim, Jong Sun ^a   Cho, Sung Bum ^a   Lee, Wan Sik ^a   Joo, Young Eun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Apoptosis; Gastric neoplasm; Livin; Prognosis

Indexed keywords

CASPASE 3; CASPASE 7; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; LIVIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN AGS; CELL STRAIN SNU638; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVIN GENE; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR INVASION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84885028936     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2724     Document Type: Article

References (31)

1. Guggenheim DE and Shah MA: Gastric cancer epidemiology and risk factors. J Surg Oncol 107: 230-236, 2013.
2. Nagini S: Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 4: 156-169, 2012.
3. Tan IB, Ng I, Tai WM and Tan P: Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol 6: 335-341, 2012.
4. Kiechle FL and Zhang X: Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta 326: 27-45, 2002.
5. Schultz DR and Harrington WJ Jr: Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 32: 345-369, 2003.
6. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
7. Brábek J, Mierke CT, Rösel D, Veselý P and Fabry B: The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal 8: 22, 2010.
8. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
9. Kenneth NS and Duckett CS: IAP proteins: regulators of cell migration and development. Curr Opin Cell Biol 24: 871-875, 2012.
10. Yan B: Research progress on Livin protein: an inhibitor of apoptosis. Mol Cell Biochem 357: 39-45, 2011.
11. Wang L, Zhang Q, Liu B, Han M and Shan B: Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther 7: 3661-3669, 2008.
12. Chang H and Schimmer AD: Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 6: 24-30, 2007.
13. Liu B, Han M, Wen JK and Wang L: Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 250: 168-176, 2007.
14. Gazzaniga P, Gradilone A, Giuliani L, et al: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14: 85-90, 2003.
15. Hariu H, Hirohashi Y, Torigoe T, et al: Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 11: 1000-1009, 2005.
16. Kim DK, Alvarado CS, Abramowsky CR, et al: Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Devel Pathol 8: 621-629, 2005.
17. Xi RC, Biao WS and Gang ZZ: Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie 34: 428-432, 2011.
18. Yagihashi A, Asanuma K, Tsuji N, Torigoe T, Sato N, Hirata K and Watanabe N: Detection of anti-livin antibody in gastrointestinal cancer patients. Clin Chem 49: 1206-1208, 2003.
19. Liang YZ, Fang TY, Xu HG and Zhuo ZQ: Expression of CD44v6 and Livin in gastric cancer tissue. Chin Med J (Engl) 125: 3161-3165, 2012.
20. Wang TS, Ding QQ, Guo RH, Shen H, Sun J, Lu KH, You SH, Ge HM, Shu YQ and Liu P: Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed Pharmacother 64: 333-338, 2010.
21. Lauren P: The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
22. Watanabe H, Jass JR and Sobin LH: WHO International Histologic Classification of Tumors: Histologic Typing of Oesophageal and Gastric Tumors. 2nd edition. Springer-Verlag, Berlin, 1990.
23. American Joint Committee on Cancer: AJCC Cancer Staging Manual: Stomach. Lippincott-Raven, Philadelphia, pp71-76, 1997.
24. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
25. Graña X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
26. Tian Y, Wan H and Tan G: Cell cycle-related kinase in carcinogenesis. Oncol Lett 4: 601-606, 2012.
27. Curtin NJ: DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12: 801-817, 2012.
28. Amoedo ND, El-Bacha T, Rodrigues MF and Rumjanek FD: Cell cycle and energy metabolism in tumor cells: strategies for drug therapy. Recent Pat Anticancer Drug Discov 6: 15-25, 2011.
29. Chen YS, Li HR, Lin M, Chen G, Xie BS, Xu NL and Lin LF: Livin abrogates apoptosis of SPC-A1 cell by regulating JNKI signaling pathway. Mol Biol Rep 37: 2241-2247, 2010.
30. Sanna MG, Duckett CS, Richter BW, Thompson CB and Ulevitch RJ: Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc Natl Acad Sci USA 95: 6015-6020, 1998.
31. Sanna MG, da Silva Correia J, Ducrey O, Lee J, Nomoto K, Schrantz N, Deveraux QL and Ulevitch RJ: IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 22: 1754-1766, 2002.